The role of body mass index in survival outcome for lymphoma patients: US intergroup experience

F. Hong, Thomas Matthew Habermann, L. I. Gordon, H. Hochster, R. D. Gascoyne, V. A. Morrison, R. I. Fisher, N. L. Bartlett, P. J. Stiff, B. D. Cheson, M. Crump, S. J. Horning, B. S. Kahl

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BBackground: The role of body mass index (BMI) in survival outcomes is controversial among lymphoma patients. We evaluated the association between BMI at study entry and failure-free survival (FFS) and overall survival (OS) in three phase III clinical trials, among patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin's lymphoma (HL). Patients and methods: A total of 537, 730 and 282 patients with DLBCL, HL and FL were included in the analysis. Baseline patient and clinical characteristics, treatment received and clinical outcomes were compared across BMI categories. Results: Among patients with DLBCL, HL and FL, the median age was 70, 33 and 56; 29%, 29% and 37% were obese and 38%, 27% and 37% were overweight, respectively. Age was significantly different among BMI groups in all three studies. Higher BMI groups tended to have more favorable prognosis factors at study entry among DLBCL and HL patients. BMI was not associated with clinical outcome with P-values of 0.89, 0.30 and 0.40 for FFS, and 0.64, 0.67 and 0.09 for OS, for patients with DLBCL, HL and FL, respectively. The association remains non-significant after adjusting for other clinical factors in the Cox model. A subset analysis of males with DLBCL treated on R-CHOP revealed no differences in FFS (P = 0.48) or OS (P = 0.58). Conclusion: BMI was not significantly associated with clinical outcomes among patients with DLBCL, HD or FL, in three prospective phase III clinical trials. The findings contradict some previous reports of similar investigations. Further work is required to understand the observed discrepancies.

Original languageEnglish (US)
Article numbermdt594
Pages (from-to)669-674
Number of pages6
JournalAnnals of Oncology
Volume25
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Lymphoma
Body Mass Index
Follicular Lymphoma
Survival
Hodgkin Disease
Phase III Clinical Trials
Proportional Hazards Models

Keywords

  • Body mass index
  • Diffuse large B-cell lymphoma
  • Follicular lymphoma
  • Hodgkin's lymphoma
  • Survival outcomes

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Hong, F., Habermann, T. M., Gordon, L. I., Hochster, H., Gascoyne, R. D., Morrison, V. A., ... Kahl, B. S. (2014). The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Annals of Oncology, 25(3), 669-674. [mdt594]. https://doi.org/10.1093/annonc/mdt594

The role of body mass index in survival outcome for lymphoma patients : US intergroup experience. / Hong, F.; Habermann, Thomas Matthew; Gordon, L. I.; Hochster, H.; Gascoyne, R. D.; Morrison, V. A.; Fisher, R. I.; Bartlett, N. L.; Stiff, P. J.; Cheson, B. D.; Crump, M.; Horning, S. J.; Kahl, B. S.

In: Annals of Oncology, Vol. 25, No. 3, mdt594, 03.2014, p. 669-674.

Research output: Contribution to journalArticle

Hong, F, Habermann, TM, Gordon, LI, Hochster, H, Gascoyne, RD, Morrison, VA, Fisher, RI, Bartlett, NL, Stiff, PJ, Cheson, BD, Crump, M, Horning, SJ & Kahl, BS 2014, 'The role of body mass index in survival outcome for lymphoma patients: US intergroup experience', Annals of Oncology, vol. 25, no. 3, mdt594, pp. 669-674. https://doi.org/10.1093/annonc/mdt594
Hong, F. ; Habermann, Thomas Matthew ; Gordon, L. I. ; Hochster, H. ; Gascoyne, R. D. ; Morrison, V. A. ; Fisher, R. I. ; Bartlett, N. L. ; Stiff, P. J. ; Cheson, B. D. ; Crump, M. ; Horning, S. J. ; Kahl, B. S. / The role of body mass index in survival outcome for lymphoma patients : US intergroup experience. In: Annals of Oncology. 2014 ; Vol. 25, No. 3. pp. 669-674.
@article{f29417b73b2348b6b9715f2004b9a30e,
title = "The role of body mass index in survival outcome for lymphoma patients: US intergroup experience",
abstract = "BBackground: The role of body mass index (BMI) in survival outcomes is controversial among lymphoma patients. We evaluated the association between BMI at study entry and failure-free survival (FFS) and overall survival (OS) in three phase III clinical trials, among patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin's lymphoma (HL). Patients and methods: A total of 537, 730 and 282 patients with DLBCL, HL and FL were included in the analysis. Baseline patient and clinical characteristics, treatment received and clinical outcomes were compared across BMI categories. Results: Among patients with DLBCL, HL and FL, the median age was 70, 33 and 56; 29{\%}, 29{\%} and 37{\%} were obese and 38{\%}, 27{\%} and 37{\%} were overweight, respectively. Age was significantly different among BMI groups in all three studies. Higher BMI groups tended to have more favorable prognosis factors at study entry among DLBCL and HL patients. BMI was not associated with clinical outcome with P-values of 0.89, 0.30 and 0.40 for FFS, and 0.64, 0.67 and 0.09 for OS, for patients with DLBCL, HL and FL, respectively. The association remains non-significant after adjusting for other clinical factors in the Cox model. A subset analysis of males with DLBCL treated on R-CHOP revealed no differences in FFS (P = 0.48) or OS (P = 0.58). Conclusion: BMI was not significantly associated with clinical outcomes among patients with DLBCL, HD or FL, in three prospective phase III clinical trials. The findings contradict some previous reports of similar investigations. Further work is required to understand the observed discrepancies.",
keywords = "Body mass index, Diffuse large B-cell lymphoma, Follicular lymphoma, Hodgkin's lymphoma, Survival outcomes",
author = "F. Hong and Habermann, {Thomas Matthew} and Gordon, {L. I.} and H. Hochster and Gascoyne, {R. D.} and Morrison, {V. A.} and Fisher, {R. I.} and Bartlett, {N. L.} and Stiff, {P. J.} and Cheson, {B. D.} and M. Crump and Horning, {S. J.} and Kahl, {B. S.}",
year = "2014",
month = "3",
doi = "10.1093/annonc/mdt594",
language = "English (US)",
volume = "25",
pages = "669--674",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - The role of body mass index in survival outcome for lymphoma patients

T2 - US intergroup experience

AU - Hong, F.

AU - Habermann, Thomas Matthew

AU - Gordon, L. I.

AU - Hochster, H.

AU - Gascoyne, R. D.

AU - Morrison, V. A.

AU - Fisher, R. I.

AU - Bartlett, N. L.

AU - Stiff, P. J.

AU - Cheson, B. D.

AU - Crump, M.

AU - Horning, S. J.

AU - Kahl, B. S.

PY - 2014/3

Y1 - 2014/3

N2 - BBackground: The role of body mass index (BMI) in survival outcomes is controversial among lymphoma patients. We evaluated the association between BMI at study entry and failure-free survival (FFS) and overall survival (OS) in three phase III clinical trials, among patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin's lymphoma (HL). Patients and methods: A total of 537, 730 and 282 patients with DLBCL, HL and FL were included in the analysis. Baseline patient and clinical characteristics, treatment received and clinical outcomes were compared across BMI categories. Results: Among patients with DLBCL, HL and FL, the median age was 70, 33 and 56; 29%, 29% and 37% were obese and 38%, 27% and 37% were overweight, respectively. Age was significantly different among BMI groups in all three studies. Higher BMI groups tended to have more favorable prognosis factors at study entry among DLBCL and HL patients. BMI was not associated with clinical outcome with P-values of 0.89, 0.30 and 0.40 for FFS, and 0.64, 0.67 and 0.09 for OS, for patients with DLBCL, HL and FL, respectively. The association remains non-significant after adjusting for other clinical factors in the Cox model. A subset analysis of males with DLBCL treated on R-CHOP revealed no differences in FFS (P = 0.48) or OS (P = 0.58). Conclusion: BMI was not significantly associated with clinical outcomes among patients with DLBCL, HD or FL, in three prospective phase III clinical trials. The findings contradict some previous reports of similar investigations. Further work is required to understand the observed discrepancies.

AB - BBackground: The role of body mass index (BMI) in survival outcomes is controversial among lymphoma patients. We evaluated the association between BMI at study entry and failure-free survival (FFS) and overall survival (OS) in three phase III clinical trials, among patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin's lymphoma (HL). Patients and methods: A total of 537, 730 and 282 patients with DLBCL, HL and FL were included in the analysis. Baseline patient and clinical characteristics, treatment received and clinical outcomes were compared across BMI categories. Results: Among patients with DLBCL, HL and FL, the median age was 70, 33 and 56; 29%, 29% and 37% were obese and 38%, 27% and 37% were overweight, respectively. Age was significantly different among BMI groups in all three studies. Higher BMI groups tended to have more favorable prognosis factors at study entry among DLBCL and HL patients. BMI was not associated with clinical outcome with P-values of 0.89, 0.30 and 0.40 for FFS, and 0.64, 0.67 and 0.09 for OS, for patients with DLBCL, HL and FL, respectively. The association remains non-significant after adjusting for other clinical factors in the Cox model. A subset analysis of males with DLBCL treated on R-CHOP revealed no differences in FFS (P = 0.48) or OS (P = 0.58). Conclusion: BMI was not significantly associated with clinical outcomes among patients with DLBCL, HD or FL, in three prospective phase III clinical trials. The findings contradict some previous reports of similar investigations. Further work is required to understand the observed discrepancies.

KW - Body mass index

KW - Diffuse large B-cell lymphoma

KW - Follicular lymphoma

KW - Hodgkin's lymphoma

KW - Survival outcomes

UR - http://www.scopus.com/inward/record.url?scp=84896809434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896809434&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdt594

DO - 10.1093/annonc/mdt594

M3 - Article

C2 - 24567515

AN - SCOPUS:84896809434

VL - 25

SP - 669

EP - 674

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

M1 - mdt594

ER -